reserved.
tions. These technical advances provide a unique opportunity to elucidate the control mechanisms operative in the early events of human B-lineage lymphopoiesis. Consequently, the analysis of the biologic activities of biochemically purified or recombinant hematopoietic growth factors on the selfrenewal and differentiation of human BCPs, identification and characterization of their receptors, and clarification of their roles in human B-lymphocyte development as well as leukemogenesis and disease progression of B-lineage lymphoid malignancies have emerged as challenging areas of intense investigation. Basic research that illuminates the immunobiologic features of human BCPs may not only lead to a coherent picture of the earliest events in the development of human lymphoid cells, but may also provide a basis for the design of more effective treatment strategies for B-lineage lymphoid malignancies and immunodeficiencies by improving our understanding of the putative regulatory lesions in their pathogenesis.
This review summarizes our current knowledge regarding the regulation of the early stages of human B-cell ontogeny and discusses the salient findings of recent studies that have examined the immunobiologic features of human BCPs. Special emphasis is placed on recent advances as well as existing controversies regarding the growth factor responses and surface antigen profiles of human lymphoid precursor cell populations in relation to distinct developmental stages within the B-precursor pathway.
DEVELOPMENTAL HIERARCHY IN HUMAN B-LINEAGE LYMPHOPOIESIS AND TEMPORAL ASSOCIATION OF SURFACE ANTIGEN EXPRESSION WITH DISCRETE STAGES OF MATURATION
The maturation of human BCPs into functional B lymphocytes represents a developmentally programmed multistep process, which is accompanied by a cascade of somatic immunoglobulin gene rearrangements,20 as well as a coordinated acquisition and loss of B-lineage differentiation antigens. 21 The characterization and classification of these antigens have been standardized during the first (Paris, France, 1982) , second (Boston, MA, 1984) , third (Oxford, UK, 1986), and fourth (Vienna, Austria, 1989) International Workshops on Human Leukocyte Differentiation Antigens, and a World Health Organization (WHO)-established CD (cluster of differentiation) nomenclature has been introduced for their identifi~ation.~"~~ To date, more than 20 biochemically distinct differentiation antigens have been identified on B-lineage cells not including the surface immunoglobulins (sIg), major histocompatibility (MHC) antigens, or the receptor proteins for defined cytokines ( Table 1) . Many of the B-lineage differentiation antigens represent functionally important surface receptors on developing B-lineage cells, and their expression is regulated by different external
While some (such as CD10, -, no effect observed: ( + effect documented but results are preliminary.
CD45, and CD73) represent membrane-associated enzymes, others (such as CD19, CD22, and B7) likely represent physiologically important cell surface bound ligands, which may play an important role in cell-to-cell interactions during B-cell development in bone marrow m i c r~e n v i r o n m e n t .~~-~~ The latter possibility is precedented by published evidence showing that many T-lineage differentiation antigens including CD2, CD4, CD8, and CD18/LFA-1 function as cellsurface bound ligands (CD2 for LFA-3, CD4 for class I1
MHC, CD8 for class I MHC, CD18/LFA-1 for I-CAM-1/ gp80). The heterophilic recognition between such surface receptors may be important for cognate surface interactions between B-lineage cells and T cells or accessory cell populations in lymphohematopoietic tissues. Other B-lineage antigens (such as CD23 and CD40) might function as surface receptors for as yet undefined soluble ~ytokines.'~ CDlO has been identified as the human membraneassociated neutral endopeptidase (enkephalinase)." Neutral endopeptidase cleaves peptides at the amino terminus of the hydrophobic residues and inactivates several peptide hormones, including glucagon and enkephalin. Thus, it is possible that CDlO molecules on B-cell precursors affect the duration of receptor occupancy and signaling by growth regulatory peptides. CD45 molecules have been identified as membrane-associated protein tyrosine phosphatases.26 Recently, Justement et al have reported elegant evidence for the involvement of CD45 in regulation of sIg-mediated signal transd~ction.~' CD45 may regulate signaling through a variety of B-cell receptors linked to phosphoinositide turnover and calcium mobilization by dephosphorylating functionally important tyrosyl residues of phospholipase C, which is activated after phosphorylation by a receptor-associated tyrosine kinase. CD73 is a membrane-associated enzyme ecto-5'-nucleotidase (ecto-5'-NT) that is anchored in the membrane by phosphatidylinositol (PI). CD73 may regulate the uptake of purines and thus play a role in B-cell maturation. 22.28 CD19, CD22, and B7 antigens are members of the Ig supergene fa mil^.^^-^' CD21 has been identified as the C3d receptor as well as a receptor for Epstein-Barr virus (EBV).28
The cytoplasmic domain of CD19 shows homology to proteins encoded by the int-1 oncogene and by EBV.29 CD19 has been proposed as a bridging molecule important for transduction of sIg-mediated signals in mature B ~e l l s .~' .~~ CD19 as a signal-transducing subunit and CD2 1 as a ligand-binding subunit linking the B cell to the complement system have been reported to form a complex on the surface of B cells which may be involved in the sIg-dependent activation. However, the function of the CD19 molecule is not dependent on the presence of sIg or CD21 because CD19 ligation results in stimulation of phosphoinositide t~r n o v e r '~ and calcium mobilization in sIg-CD21-BCP populations and modulates their proliferative a~t i v i t y .~' .~~ CD22 displays a high degree of homology to the myelin-associated glycoprotein (MAG), a neuronal surface adhesion molecule mediating cell-to-cell contact during myelogenesis, and it may be involved in cell-to-cell interactions between B cells and monocyte^.^' Furthermore, CD22 may also be important for transduction of sIg-mediated signals." Most recently, the natural ligand of B7 antigen has been identified as the CD28 T-cell activation antigen, which is another member of the Ig ~uperfamily.~' CD28-B7 mediated adhesion between activated B cells and T cells might be important for T-cell regulation of antigen-specific B-cell responses.
CD20 directly regulates transmembrane Ca flux in B lymphocytes and has been shown to serve as a substrate for protein kinase C (PKC).39 Thus, CD20 molecule may play an important role in the regulation of B-cell activation. CD23 has been identified as the low affinity Fc receptor for IgE and may be the receptor for a B-cell growth factor.28 CD40 may physiologically function as the surface receptor for an important growth regulatory signal in human B-cell d e~e l o p m e n t .~~ CD40 shows structural similarities to a number of growth factor receptors and a striking homology with nerve growth factor receptor.34 Agonistic anti-CD40 monoclonal antibodies (MoAbs) have a growth-promoting activity on B-lineage lymphoid cells at the pro-B, pre-pre-B, pre-B, as well as mature B stages and can maintain B-cell viability and alertness even in the absence of a second competence signal. 34 We have recently shown that CD40 receptor is coupled to at least two transmembrane postreceptor signaling pathways, namely the adenylate cyclase-CAMP-protein kinase A cascade and the phospholipase C-inositol 1,4,5-trisphosphate-protein kinase C cascade.34 The ligation of CD40 receptor generates a complementary intracellular signal which can modulate regulatory signals of other receptors, such as sIg, CD19, and low molecular weight B-cell growth factor receptor.34 Hence, CD40 may represent a multifunctional receptor which is involved in the crosstalk between different B-cell receptors. CD74 has been identified as the surface expressed MHC class I1 associated invariant chain (Ii).28 Intracellulary the invariant chains are noncovalently associated with M H C class I1 antigens. They are directly involved in antigen processing and presentation.
Currently, very little is known about the physiologic function of the B-lineage surface antigens during early stages of human B-cell ontogeny. However, the isolation of efficient expression vectors that encode human B-lineage differentiation antigens, a revolutionizing development in B-cell immunobiology pioneered by Stamenkovic and Seed at Harvard Uni~ersity,~~.~' should allow researchers to elucidate the function of these surface molecules in relation to distinct developmental stages and to determine their natural ligands. With improving knowledge regarding the physiologic function of B-lineage surface antigens, a better understanding of the temporal association of their orderly acquisition, expression, and loss with discrete stages of development is likely to help us understand the regulation of human B-cell ontogeny.
Surface antigen profiles of leukemic BCP populations. The current hypothetical models of human B-lymphocyte ontogeny and the developmental hierarchy of Ig gene rearrangements and antigen expression are largely based on studies performed on leukemic BCPs from B-lineage acute lymphoblastic leukemia (ALL) p a t i e r~t s .~l -~~*~'~~~ B-lineage ALLs are thought to originate from putative developmental lesions in normal BCP clones during early phases of ontogeny, which allegedly lead to a maturational arrest at discrete stages of B-lineage lymphop~iesis.~' In a recent report, use only. 
Such models and B-lineage differentiation diagrams based on the phenotypic features of leukemic BCPs helped to identify transitional BCP compartments within the human B-precursor pathway. However, the inferred conclusions regarding the coordinate sequence of antigen expression or Ig gene rearrangements during human B-cell ontogeny are obligatorily speculative. Leukemic phenotypes may be altered by clonal evolution during and/or after the malignant transformation of a given target BCP clone or a misprogramming of differentiation in leukemic BCPs. Therefore, the immunophenotypic or genotypic traits of leukemic BCPs may not accurately reflect the phenotypes of the original BCP clone before transformation. Furthermore, several allegedly aberrant phenotypes have been observed in B-lineage ALLs, including mixed lineage or bipotential phenotypes,50s5' for which these hypothetical models have failed to provide a straightforward explanation. Greaves et have proposed that the coexpression of myeloid-lineage or T-lineage markers on leukemic BCPs reflect a transient "lineage promiscuity" in early stages of ontogeny rather than "lineage infidelity" as a result of a misprogramming during leukemic transformation For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From based on the speculation that the absence of a B-lineage differentiation antigen on a BCP population expressing another B-lineage antigen is exclusively due to an earlier acquisition of the latter antigen during human B-cell devel~pment.'~ In my opinion, it is virtually impossible to accurately assess the coordinate sequence of antigen expression in human B-cell ontogeny by a single time point multiparameter flow cytometric determination without analyzing the dynamic changes in immunophenotype (or, alternatively, the expression of the genes encoding the relevant antigens) in an assay system, which allows for B-lineage differentiation.
In order to more carefully study and monitor the developmental hierarchy of antigen expression along the B-precursor pathway, we have recently developed an in vitro clonal assay which appears to permit B-lineage differentiation of fetal BCPS.~' We used this model system in combination with multiparameter flow cytometry and cell sorting to study the early stages of normal human B-cell differentiation in fetal liver.3s Three immunologically distinct normal BCP populations were identified among the lymphoid cells from human fetal livers based on the correlated expression of CDlO and CD19 antigens. CDlO+CD19-BCPs were found in larger numbers than CDlO+CD19+ or CDlO-CD19+ BCPs, they acquired CD19 antigen in vitro, and their day 7 progeny in BCP colonies displayed a more immature immunophenotype than the progeny of CDlO+CD19+ B C P S .~~ These findings indicate that CDlO antigen expression precedes the acquisition of CD19 antigen, and CD19 expression is developmen- CD10, and CD19 usually precede the acquisition of CD20, CD21, CD22, CD23, CD24, CD37, CD38, CD39, CD40, CD72, CD73, CD74, CD75, CD76, CD77, CD78, sIgD, and sIgM, confirming and extending the observations of Loken et A schematic representation of the sequential expression of B-lineage differentiation antigens is presented in Fig 1. Our model is based on detailed multiparameter flow cytometric analyses of fresh and cultured normal human fetal liver and fetal bone marrow BCPs as well as fresh and cultured leukemic BCPs from B-lineage ALL patients. Although this model assigns a discrete maturational stage for the vast majority of BCP phenotypes and appears to accommodate available data on the surface antigen profiles of normal and leukemic BCPs, it certainly does not exclude the possibility that multiple pathways of differentiation exist in human B-lineage lymphopoiesis, as will be discussed hereinbelow.
While our findings establish that 18 differentiation antigens are acquired at a later stage of B-cell ontogeny than HLA-DR, CDlO, and CD19, they differ from those of Loken et a1" with respect to acquisition of sIgM on normal BCPs. Specifically, our data indicate that sIgM is acquired on some BCPs early in fetal B-cell development, following the expression of HLA-DR, CDlO, CD19, and CD72, but preceding the expression of CD20, CD21, CD22, CD24, CD37, CD38, CD39, CD73, CD74, CD75, CD76, CD77, Bgp95, sIgD, H-BCGF R, and, occasionally, CD40 and CD78. In contrast, CD221B3  CD23  CD24  CD25  CD34  CD37  CD38  CD39  CD40  CD45  CD72  CD73  CD74  CD75  CD76  CD77  CD78 lymphoid tissues.6' Alternatively, multiple BCP differentiation pathways may exist and the dominant immunophenotype may depend on the selective pressure of a given micr~nvironment. Perhaps human BCPs do not follow a strictly ordered series of differentiation steps in a given human lymphopoietic microenvironment to generate mature Ig-producing B-lymphocytes. Indeed, the identification of CDlO+CD19+sIgM+ BCPs lacking CD20, CD21, CD22, CD24, and CD40 antigens, along with CD1O+CD19+sIgM-BCPs expressing CD20, CD21, CD22, and CD40 in fetal hematopoietic tiss~es,f~+~* strongly suggests that parallel pathways of B-precursor differentiation may exist in human B-lineage lymphopoiesis and prompts the hypothesis of flexible developmental programs with multiple differentiation options. Such parallel pathways might differ not only in sequential antigen expression, but afso in time kinetics of transition through the individual maturational stages, and they may communi~te with each other at several levels.
Their existence may play a pivotal role in the generation of an appropriately balanced B-cell immune response to a given challenge by ensuring the necessary flexibility. The functional properties of CDlO+CDl9+sIg~-and CDlO+CD19+ sIgM+ BCPs may also be distinct; while the former may represent B-lineage lymphoid progenitor cells responsible for the long-term maintenance of the B-lineage lymphoid compartment, the latter may be involved in a rapid production of 
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Hurwitz et al failed to detect normal BCP populations corresponding to the immunophenotypes of leukemic BCPs from a large fraction of B-lineage ALLs (CDlO-CD19+ cells were not identified).50 After comparing the immunophenotypic features of leukemic and normal BCPs, these investigators further concluded that the majority of B-lineage ALLs exhibit an asynchronous antigen expression:' and based on this apparent developmental asynchrony, they challenged the validity of B-lineage ALL as a model system for normal B-lineage lymphopoiesis. Obviously, the findings of Loken, Hurwitz, and Ryan et a1'5*17*50 do not exclude the possibility that some of the "unusual" immunophenotypes in B-lineage ALL represent rare normal BCPs. These BCP subpopulations may have been missed in adult bone marrow because of the inability of the current technology to detect such rare cell populations. In contrast to the reported findings of Hurwitz et a1,50 we were able to identify CDlO-CD19+,CD22+CD34+, as well as CDlO+CD22+ BCPs in fetal liver and fetal bone marrow. Therefore, our findings are not in accordance with the concept of asynchronous antigen expression in B-lineage ALL. This discrepancy may be due to the remarkably higher frequency of human BCP populations in fetal liver and fetal bone marrow as compared with adult bone marrow. Alternatively, these distinct BCP populations displaying the surface antigen profiles of patient-derived leukemic BCP populations might suggest that ALLs originate from clonal expansion of persisting fetal BCP populations.
Biphenotypic lymphocyte precursor cell populations. Lymphocyte precursors committed to either B-or T-lineage differentiation pathways in human lymphocyte ontogeny have been speculated to possess a common lymphoid progenitor cell. However, direct evidence for the existence of biphenotypic lymphocyte precursors has not been reported. The current paucity of knowledge regarding biphenotypic lymphoid precursors probably reflects the low incidence of this putative cell population in human hematopoietic t i s s~e s .~~,~~ During detailed immunophenotypic analyses of marrow blasts from a large series of ALL patients, a very small percentage of TdT+HLA-DR+CD34+ cases coexpressing CD2 and CD19 antigens at the single cell level were identified!' Notably, leukemic blasts from these ALL patients differentiated to the pre-B cell stage after stimulation with the phorbol ester 12-0-tetradecanoylphorbol-13-acetate (TPA) as evidenced by acquisition of CD20 and Cp and partial loss of CD2, indicating that CD2/CDl9 coexpression is developmentally programmed in human lymphocyte ontogeny and reflects a distinct stage of mat~ration.6~ This hypothesis was corroborated by the detection of a small population of CD2+CD19+ lymphoid cells in fetal hematopoietic organs, which may represent the putative normal counterparts of the biphenotypic leukemic lymphocyte precursors in CD2+CD19+ ALL.63 We were able to establish a TdT+ HLA-DR+CD2+CD19+ normal fetal liver lymphoid precursor cell line with germline configuration for Ig heavy chain genes.63 Substantial evidence from both in vivo and in vitro morphology studies shows that direct stromal cell-hematopoietic cell contact is important in murine B-lineage lymphopoiesis and the differentiation of BCPs only occurs when direct stromal cell contact is ~ermitted!~-~* We postulate that the interaction of the CD2+CD19+ precursor cell with stromal cells may play a critical role in the commitment to develop along the B-lymphocyte pathway. One may postulate that the CD2/LFA3 intera~tion~~ is important in early B-cell maturation in fetal liver and fetal bone marrow by mediating adhesion between biphenotypic lymphocyte precursors and epithelial/stromal cells, which provide the necessary hematopoietic growth fa~tors!~. ~~ We used the data on the immunologic marker profiles of biphenotypic ALL blasts and their progeny, as well as the immunologic marker profiles of CD2+CD19+ and CD2-CD19+ normal fetal liver lymphoid precursor cell lines, to develop a hypothetical model of early B-lineage commitment and differentiation of biphenotypic lymphocyte precursors. According to this model, shown in Fig 2, at least five stages of maturation can be identified based on the developmental hierarchy of acquisition of lymphocyte differentiation antigens on biphenotypic lymphocyte precursors. The most immature biphenotypic lymphocyte precursor in fetal lymphopoiesis (stage 1) expresses nuclear TdT and the surface antigens CD2, CD10, and CD19, but lacks the differentiation antigens CD20, CD21, CD22, or c p /~I g .~' Acquisition of CD22 identifies the next stage of development (stage 2) of biphenotypic lymphocyte precursors. During the subsequent stage of development (stage 3) biphenotypic lymphocyte precursors acquire CD21 antigen. With acquisition of CD20 and loss of CD2, stage 3 precursors differentiate into stage 4 lymphocyte precursors and subsequently to a pre-B cell stage (stage S), which is characterized by the coexpression of CD19, CD20, and Cp! ' While this hypothetical model does not exclude the possibility that alternative pathways exist in early stages of human lymphocyte development, it provides critical information and possible explanation for the origin of biphenotypic ALL. Intriguingly, one of the CD2+CDlO+CD19+ biphenotypic ALL patients relapsed with CD2-CDlO+CD19+ B-lineage ALL (OBrien and Uckun, unpublished observations), providing evidence that the biphenotypic lymphoid precursors in CD2+CD19+ ALL retained their abilities to exploit the normal B-lineage differentiation program and to undergo phenotypic changes in vivo reminiscent of the TPA-induced changes in vitro and consonant with B-lineage differentiation!' Besides CD2+ CD 19+ biphenotypic lymphoid precursors, we also identified some CD7+CD19+ biphenotypic lymphoid precursors in normal fetal hematopoietic tissues and in some ALLs. Their immunobiologic features and their alleged ability to adopt both B-lineage and T-lineage differentiation options are currently being investigated in our laboratory.
The occurrence of biphenotypic leukemias with lymphoid and myeloid features such as CD19+CD13+ B-lineage lymphoid/myeloid leukemia^,^'.^^-^^ the detection of lymphoid cells in the mixed colonies derived from human bone marrow progenitor cells77; the clonal origin of myeloid, erythroid, and lymphoid cells in chronic myelocytic leukemia (CML)78*79; and phenotypic interconversion between myeloid and lymphoid lineages in some provide suggestive evidence for the existence of bipotential myeloid-lymphoid progenitor cells in the human hematopoietic system. More use only. recently, we were able to isolate CD19+CD13+ biphenotypic B-lineage lymphoid/myeloid progenitor cells from fetal bone marrows and fetal livers, which likely represent the putative normal counterparts of leukemic blasts from CD19+CD13' biphenotypic acute leukemia patients. The immunobiologic features of normal and leukemic biphenotypic lymphoid/ myeloid progenitors, in particular their in vitro and in vivo proliferative and differentiative capacities, are currently being investigated in our laboratory.
REGULATORY ROLES OF HEMATOPOIETIC GROWTH FACTORS IN HUMAN B-LINEAGE LYMPHOPOIESIS
While very little was known about the growth regulators of human BCPs because of lack of appropriate assay systems, short-term colony assays and later long-term culture systems for murine BCPs provided the underlying basis for the long-term in vitro culture system that supported the selective growth of murine BCPs was first established by Whitlock and Witte68.98 and provided a unique opportunity to study the regulated growth and differentiation of murine BCPs and their more mature progeny. Until recently, culture conditions that favor the proliferation of human BCPs were undetermined. The paucity of knowledge about the immunobiologic features of human BCPs prompted a considerable effort to devise experimental model systems and cell culture techniques for studying the growth factor responses of human BCPs at distinct developmental stages. B-cell precursors a t discrete stages of B-cell ontogeny. This information is detailed in the following section.
Growth factor responses of leukemic B-cell precursors. Most of the information regarding growth regulatory signals during early phases of human B-cell ontogeny has been inferred from studies of leukemic BCPs. Izaguirre et allo7 pioneered the development of short-term culture systems for leukemic human BCPs by establishing an in vitro soft-agar colony assay for common B-lineage ALL blasts. Using special incubator chambers with low oxygen tension, irradiated feeder cells, and conditioned media from phytohemagglutinin (PHA) stimulated lymphocytes, these investigators were the first to successfully grow CDlO+sIg-leukemic BCPs from freshly obtained bone marrow samples of B-lineage ALL patients."' More recently, a methylcellulose colony assay system that permits the growth of freshly isolated CD10+ as well as CDlO-leukemic BCPs from B-lineage ALL patients was developed in my laboratory." This experimental model system, combined with multiparameter cell sorting, ligand binding assays, and Scatchard analyses, provided the basis for a detailed investigation of the growth factor receptor profiles of leukemic BCPs corresponding to discrete stages of development within the B-lineage lymphoid differentiation pathway, and a comparative analysis of the biomodulatory activities of hematopoietic growth factors on growth and differentiation of leukemic BCPs.
Our initial studies have shown a growth stimulatory activity for the supernatants of lectin-stimulated T-lymphocytes as well as activated helper T-cell clones. This observation provided corroborative evidence for the existence of soluble growth factors stimulatory for human BCPs,loJ' as initially proposed by Landreth et alios based on their detection of a pre-B cell growth factor in the urine specimens from a patient with cyclic neutropenia. We next sought to identify the specific growth factor(s) stimulating leukemic BCP colony formation. For this purpose, we first investigated the expression of human B-cell growth factor receptors on leukemic BCPs from B-lineage ALL patients.'' Receptor binding assays using radioiodinated preparations of low molecular weight B-cell growth factor (L-BCGF; 12 to 20 Kd) purified by Mehta et a1 from supernatants of lectinstimulated T-lymphocytes,lo9 and high-molecular-weight B-cell growth factor (H-BCGF; 60 Kd) purified by Ambrus et a1 from supernatants of a Burkitt's lymphoma cell line,IIO provided direct evidence for the constitutive expression of approximately 40,000 L-BCGF and approximately 3,500 Besides biochemically purified L-BCGF and H-BCGF from natural sources, recombinant (r) interleukins (IL) 1 through 7 have also been tested for their bioactivities on leukemic BCPs. Touw et a1 first reported that leukemic BCPs can be induced to express functional IL-2 receptor proteins, and rIL-2 can augment leukemic BCP colony formation on irradiated leukocyte feeders.Il4 This initial observation regarding rIL-2-induced stimulation of leukemic BCPs could not be confirmed by other investigator^.^^."^.^^^.^^^ P robably, the stimulatory effects of IL-2 reported by Touw et a1 were mediated by IL-2 responsive nonleukemic accessory cell populations.
Human rIL-3 was theaext candidate hematopoietic growth factor tested for its stimulatory effects on leukemic BCPs. Palacios et a1 had previously demonstrated that murine IL-3 stimulates the proliferative activity, of murine BCPs, pro-B and pre-B clones.82s84 In light of the structural and functional relationships between murine IL-3 and human IL-3,6,7,'9 we postulated that human rIL-3 may stimulate the proliferation of human leukemic BCPs. To test this hypothesis, we analyzed the bioactivities of human rIL-3 on leukemic BCPs from ALL patients as well as ALL cell lines.II7 Human rIL-3 stimulated the proliferative activity of freshly isolated leukemic BCPs in 42% of the B-lineage ALL cases in a dosedependent fashion and half-maximal stimulation was observed at 17 to 34 pmol/L of rIL-3.II7 Scatchard plot analysis of the specific equilibrium data for IL-3 responsive leukemic QCPs with composite immunophenotypes corresponding to pre-B (CD19+CD10+CptsIg-) or pre-pre-B (GD19+CDlO+ Cp-sIg-) stages of human B-cell ontogeny yielded astraight linear regression line, indicating the existence of a single class of 60 to 210 high affinity IL-3 binding sites/cell with a Ka value of 0.4 to 0.6 x 10'' M-'."' The concentration of IL-3 required to produce 50% maximal receptor occupancy (kd = dissociation constant) ranged from 170 to 280 pmol/L, which was tenfold higher than that required to induce 50% maximal proliferative response in leukemic BCP colony assays.'I7 Hence, partial ligand occupancy of low numbers of high-affinity IL-3 receptors was sufficient for stimulation of leukemic BCPs. This study was confirmed by Park et al,"' who reported that '251-labeled human rIL-3 bound to leukemic BCP (pre-pre-B and pre-B ALL) cell lines via a single class of high-affinity receptors (t500 receptors/cell) with a Ka value of 1 BCGFs provide the strongest growth stimulatory signal to leukemic BCPs. Conceivably, other hematopoietic growth factors exert an autostimulatory function by either stimulating autocrine BCGF production or delivering a competence signal and/or amplifying proliferative responses to exogenous or autocrine BCGFs. L-BCGF, H-BCGF, IL-3, as well as IL-1 stimulate the proliferative activity of leukemic BCPs without inducing differentiation along the B-precursor pathway.lS.l 17,120 This observation may be biologically significant because uncoupling of proliferation and differentiation may provide the basis for uncontrolled growth and clonal expansion of BCP populations, originally proposed by Although all four of these growth factors are capable of stimulating leukemic BCPs from some ALL patients, the number of growth factors that stimulate leukemic BCPs as well as the extent of stimulation by a particular growth factor that varies between patients.'8~11'~113~117~119~120 Ligand binding studies using radiolabeled L-BCGF, H-BCGF, IL-3, and IL; 1 provided conclusive evidence for quantitative interpatient variations growth factor receptor numbers.18~117.120 These findings indicate a marked heterogeneity in the composite growth factor receptor profiles of leukemic BCPs, and/or the function of specific growth factor receptors. I speculate that functional growth factor receptors are expressed in an orderly fashion during human B-cell ontogeny and the composite growth factor receptor profiles of BCPs may be used to define discrete stages of development. In this regard it is noteworthy that, unlike L-BCGF, H-BCGF, and IL-3, IL-4lB-cell stimulatory factor 1 (BSF-l), IL-S/B-cell growth factor I1 (BCGF 11), IL-6/BSF-2, or IL-7 do not stimulate the in vitro proliferation and colony formation of leukemic BCPs from newly diagnosed or relapsed ALL patients (Uckun and Ledbetter, unpublished observations). It is conceivable that several contemporaneous and distinct modes of regulation are used at different developmental stages of B-lineage lymphopoiesis to precisely orchestrate this rather complex multistep process. Some of these distinct regulatory modes could be involved in normal steady state B-cell production, whereas others may be involved only in various situations of reactive (such as inflammation, trauma, immuuse only.
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The observed interpatient differences in growth factor response patterns of leukemic BCPs may thus be due to a differentiation-linked modulation of growth factor receptor expression/function. However, the data from studies on leukemic BCPs should be interpreted with due caution because leukemogenic events, malignant transformation, and/or subsequent clonal evolution may alter the growth factor receptor profiles and growth factor response patterns of target BCP populations differently among patients. Nowell et a1 have proposed that structural chromosomal abnormalities, including those most frequently encountered in leukemic BCPs, may alter the expression of oncogenes, and these alterations may modulate postreceptor signaling after stimulation with a growth factor."' Intriguingly, we found a pronounced association between the proliferative responses of leukemic BCPs to L-BCGF/H-BCGF and their cytogenetic features." The responses to PHA-LCM, L-BCGF, as well as H-BCGF were significantly higher for leukemic BCPs with structural chromosomal abnormalities than for leukemic BCPs without structural chromosomal abnormalities." Most notably, leukemic BCPs with structural abnormalities involving the bands pll-13 on the short arm of chromosome 12 displayed a significantly greater proliferative H-BCGF response than leukemic BCPs with other chromosomal aberrations or a normal diploid karyotype." C-Kras 2 oncogene has been mapped to 1 2~1 2 on the short arm of chromosome 12. These observations suggested the possibility of a link between ras oncoproteins and H-BCGF response. The hypothesis that the events of malignant transformation and clonal evolution may directly influence the growth factor responses of leukemic BCPs was supported by our recent studies, which showed distinct differences between the growth factor responses of leukemic BCPs and their putative normal counterpart^.'^ Additional corroborative evidence for an association between clonal evolution during disease progression and growth factor receptor profiles of leukemic BCPs was obtained in a recent study on in vitro proliferative response patterns of leukemic BCPs to L-BCGF, H-BCGF, and IL-1: 100% of relapsed B-lineage ALLs responded to L-BCGF, H-BCGF, as well as IL-1, while only 13% of newly diagnosed B-lineage ALLs responded,12' suggesting that leukemic BCP clones may be subject to selective pressure in clonal evolution. Leukemic BCP subclones expressing receptors for multiple growth factors would seem more likely to show a selective growth advantage and become the predominant clone at relapse than BCP subclones with a restricted growth factor response pattern. Finally, the observed heterogeneity in growth factor receptor expression and growth factor responses may also be partially due to genetic polymorphisms, as it has been proposed by Kincade et a1 for murine B C P S .~~ While leukemic BCPs provide a valuable model system to elucidate the effects of hematopoietic growth factors on human BCP populations a t discrete stages of B-cell development, numerous difficulties pervade immunobiologic studies on leukemic BCPs. Leukemic BCPs are arrested at only a few specific stages of B-lineage lymphopoiesis. The physiologic role of a Growth factor responses of normal BCPs.
given growth factor might not be consistent throughout the early B-cell ontogeny. Therefore, it is difficult to predict the role of growth factors in early stages of human B-cell development based on their effects on leukemic BCPs. Another difficulty arises from presumptions made about the similarities between leukemic BCPs and their putative normal counterparts. As discussed earlier in this review, regulation of proliferation and differentiation steps are likely to be deranged in leukemic BCPs as a result of the primary leukemogenic event and subsequent clonal evolution. We have recently developed a new experimental approach to more carefully study the role of hematopoietic growth factors in human B-cell ontogeny, and to analyze the surface antigen and growth factor receptor profiles of normal BCP populations as they differentiate along the B-precursor pathway. An in vitro colony assay for normal BCPs from fetal hematopoietic tissues was combined with multiparameter flow cytometry and cell sorting3' to directly compare the immunobiologic features of normal and leukemic BCPs and to identify those hematopoietic growth factors, which act on BCPs during normal B-cell ontogeny.
Similar to leukemic BCPs, FACS sorted CDlO+CD19+ and CDlO+CD19-normal BCPs from fetal bone marrows and fetal livers show a marked proliferative response to L-BCGF and rIL-3,35 but not to rIL-4, rIL-5, or rIL-6. Thus, L-BCGF and IL-3 may play an important growth regulatory role both in normal B-lineage lymphopoiesis as well as clonal expansion of leukemic BCPs in B-lineage ALL. Unlike leukemic BCPs, normal BCPs fail to respond to H-BCGF or rIL-1 .35.'20 These differences may be due to altered/amplified H-BCGF and IL-1 receptor gene expression in leukemic BCPs. As mentioned earlier, rIL-7 does not stimulate leukemic BCPs from ALL patients. Similarly, most normal BCPs lack IL-7 receptors. However, a subpopulation of very immature fetal liver BCPs with germline immunoglobulin genes (ie, pro-B cells) express functional high-affinity IL-7 receptors and show a marked proliferative response to rIL-7. This response is mediated by stimulated phosphoinositide turnover and calcium mobilization.12' Another distinct difference exists between normal and leukemic BCPs relative to the function of their surface CD19 re~eptors.~'.~' Ligation of the CD19 receptor augments the proliferative L-BCGF responses of CD19+ leukemic BCPS,~'.~~.~' but inhibits the L-BCGF induced proliferation of CD19+ normal BCPs3'x6' and B ~e l l s .~~~.~~~ This prompts the hypothesis that the function of the CD19 receptor and/or the CD19 linked signal transmission pathways may be altered during leukemogenesis and/or subsequent clonal evolution in human B-lineage ALLs.
Ongoing comparative studies of normal versus leukemic BCPs should enhance our understanding of the key regulatory events in early stages of B-cell ontogeny. Qualitative or quantitative alteration of a growth-regulatory process in leukemic BCPs might indicate the physiologic importance of this process in the orderly regulation of human B-cell ontogeny and prevention of defective proliferation. An improved comprehension of the key regulatory events would also have a major impact on the design and choice of therapeutic regimens in B-lineage leukemias. 125 The presentation of regulatory growth factors to murine BCPs in the context of bone marrow stroma is believed to be as important as their presence in the marrow microenvironment. Glycosaminoglycans from the bone marrow stroma are capable of accumulating hematopoietic growth factors and presenting them in the biologically active form to hematopoietic cell^.'^^.^*' Gordon et a1 have reported that selective compartmentalization of growth factors by glycosaminoglycans in the bone marrow microenvironment may be an important regulatory biofunction of the marrow stroma.126 Human B-lineage lymphopoiesis is also believed to take place in the bone marrow microenvironment in close association with stromal elements. This hypothesis is predicated on the supposition that the fundamental general concepts of murine B-cell physiology should also apply for Recently, we examined the effects of commercially available defined biomatrix products including laminin and fibronectin on the growth factor responses of human normal and leukemic BCP populations. The proliferative responses of BCPs to L-BCGF, as well as rIL-3, were enhanced in the presence of laminin as well as fibronectin (Oubaha and Uckun, unpublished data). These preliminary findings suggest that biomatrix components can affect growth factor responses of human BCPs. Several groups, including my own, are now studying the effects of growth factors and growth factor combinations on normal and leukemic BCPs in the context of fetal liver/fetal bone marrow stromal cells and SV40 transformed stromal cell l i n e~. '~l *~~~ Studies of the bone marrow microenvironment and BCP-stroma interactions are essential to a better understanding of the regulatory events in human B-cell ontogeny. Furthermore, it is quite possible that growth factors elaborated by stromal elements and distinct from known lymphokines regulate or coregulate human B-lineage lymphopoiesis in the bone marrow microenvironment.
In vivo model systems for human B-lineage lymphopoiesis. In vitro model systems for B-lineage lymphopoiesis clearly lack the complexity of the bone marrow microenvironment. Recently, McCune et a1 have described a novel in vivo model system for human lymphohematopoiesis, which uses mice with genetically determined severe combined immunohuman &cell physiology.6-9.66,90,121,1z8-130 deficiency (SCID)."' Human fetal liver, lymph node, and thymus have been shown to support human myelopoiesis and lymphopoiesis in this mouse model.133 A similar system has subsequently been used by Kamel-Reid et a1 to assess the in vivo proliferation of human hematopoietic cells and leukemic
The availability of in vivo models for human BCPs provides a new testing ground to study the effects of recombinant growth factors on proliferation and differentiation of normal and leukemic BCPs. The combined use of in vivo models for human lymphopoiesis with multiparameter flow cytometry and cell sorting should allow a comparative analysis of the in vivo self-renewal and differentiative capacities of immunophenotypically distinct BCP subpopulations as well as the developmental potential of uncommitted lymphohematopoietic precursors.
CONCLUSION AND FUTURE PERSPECTIVES
A unique opportunity to amplify our knowledge regarding the regulation of human B-lineage lymphopoiesis has been provided by recent technical advances in immunobiology. Clonal assays for human BCPs have been developed and multiparameter flow cytometry, as well as cell sorting techniques, have improved. More recently, in vivo model systems for human lymphohematopoiesis using SCID mice have been constructed, and a broad panel of MoAbs reactive with BCP-associated antigens and recombinant growth factors are available. Ongoing and projected studies of normal and leukemic BCPs should expand and clarify information on the basic immunobiologic features of human BCPs. The knowledge that will result from these studies will not only improve our understanding of the earliest events in the development of human B-lineage lymphoid cells, but may also help us to design more effective treatment for diseases such as B-lineage ALL and SCID. Further strategies against B-lineage ALL might include disrupting growth factor/growth factor receptor interactions using antibodies to growth factors or growth factor receptors, inducing terminal differentiation using growth factors or using i m m~n o t o x i n s l~~* '~~ against leukemic BCP-associated surface antigens. In the case of immunodeficiencies involving B cells and BCPs, expanding the normal BCP pool using growth factors might emerge as a new and effective therapeutic modality. In addition, greater comprehension of normal BCPs could lead to the development of optimized procedures for isolation, cultivation, and preservation of human BCPs. This development could offer enormous clinical advantages for the application of a BCP replacement therapy in immunodeficiencies. Finally, a better understanding of the immunobiologic differences between normal and leukemic BCPs may elucidate the putative genetic alterations responsible for the malignant transformation of human BCPs, the multistep evolution of emerging leukemic BCP clones, and the role of lymphokines in the leukemogenesis of B-lineage ALL. 
